Pancreas 2000

This trial has now closed.




A randomised prospective open label, pragmatic multi-centre trial on the effect of early enteral nutrition on gut barrier permeability in severe acute pancreatitis. Patients will be randomised to receive either early enteral nutrition or standard fluid replacement.


Inclusion Criteria

Table: Marshall score. Yellow cells meet the inclusion criteria

Organ System Sequential Organ Failure Assessment Score
0 1 2 3 4
Respiratory PaO2/FIO2 >400 ≤400 ≤300 ≤200* ≤100*
Renal creatinine, μmol/L ≤110 110-170 171-299 300-440
Urine output ≤500 mL/day
>440
Urine output <200 mL/day
Hepatic bilirubin, μmol/L ≤20 20-32 33-101 102-204 >204
Cardiovascular hypotension No hypotension MAP <70 mm Hg Dopamine ≤5†

Dobutamine (any dose)
Dopamine >5† or
epinephrine ≤0.1† or
norepinephrine ≤0.1†
Dopamine >15† or
epinephrine >0.1† or
norepinephrine >0.1†
Haematologic platelet count, x10¹²/L >150 ≤150 ≤100 ≤50 ≤20
Neurologic Glasgow Coma score 15 13-14 10-12 6-9 <6

MAP, mean arterial pressure; * Requires the use of respiratory support; † adrenergic agents administered ≥1 hr (doses are in μg/kg/min).


Patient Exclusions


If you require any help, please contact:

Hemant Kocher
Tel: +44 (0) 20 7014 0400

ISRCTN 12838218

Cancer Research UK Barts and The London  

Randomisation service provided by: Sealed Envelope™.com